Equity Overview
Price & Market Data
Price: $11.06
Daily Change: -$0.05 / 0.45%
Range: $10.77 - $12.04
Market Cap: $1,256,792,064
Volume: 1,568,118
Performance Metrics
1 Week: 35.37%
1 Month: -1.78%
3 Months: -19.39%
6 Months: -66.88%
1 Year: -56.53%
YTD: -53.06%
Company Details
Employees: 191
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.